Access requires that you are 21 years of age or older. Products are for laboratory and research use only — not for human or veterinary use, consumption, or clinical application.
BPC-157 reference material, supplied as a lyophilized powder in a sealed vial for in-vitro laboratory research and analytical method development. Each fill size is a separate SKU. Lot and COA records are shown when assigned.
This listing is a research chemical / reference material. No therapeutic, preventive, or diagnostic claims are made or implied. The storefront displays only approved analytical characterization data released through its public report records.
BPC-157 is a synthetic pentadecapeptide of 15 amino acids. Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV). Molecular formula C62H98N16O22, molecular weight 1419.55 Da. CAS 137525-51-0. A partial N-terminal sequence of Body Protection Compound, a protein described in human gastric juice. The peptide shows no sequence homology with known intestinal peptides.
Roughly 27% of residues are proline, which makes the backbone conformationally rigid and accounts for its reported stability in water and in gastric juice.
First described in the early 1990s at the University of Zagreb as a peptide fragment of a protein isolated from human gastric juice, and characterised in a 1993 publication. Synthesis routes were subsequently developed by DIAGEN d.o.o. in Slovenia, replacing biochemical extraction from gastric juice. It has appeared in preclinical literature under the developmental codes PL 14736 and PL-10. First described by Predrag Sikirić and colleagues, University of Zagreb, Croatia (1993).
Studied almost exclusively in preclinical models of tissue repair — tendon, ligament, muscle and gastrointestinal mucosa — and in angiogenesis and cytoprotection assays. Vectra supplies it as a reference material for in-vitro laboratory research and analytical method development only.
A 2025 literature and patent review notes that a PubMed search returns over 190 articles referencing BPC 157, and that more than 80% list P. Sikirić or S. Seiwerth as first or senior author; independent replication is limited to a small number of in-vitro and short-term rodent studies. No pathway is confirmed in human tissue at clinical level.
Not approved as a medicinal product in any jurisdiction. Placed in FDA 503A Category 2. No therapeutic, preventive, or diagnostic claims are made or implied.
Not approved as a medicinal product in any jurisdiction. Not approved by EMA or MHRA. Australia's TGA lists it as Schedule 4 (Prescription Only), effective October 2025. Current FDA position: Removed from 503A Category 2 (Federal Register 2026-07361, effective 2026-04-22); not added to Category 1. Awaiting FDA determination and rulemaking following the July 2026 advisory recommendation. Vectra supplies this material as a research-use-only reference material. No therapeutic, preventive, or diagnostic claims are made or implied.
Yes. The FDA Pharmacy Compounding Advisory Committee considered it at its July 23–24, 2026 meeting. The committee's vote was: recommended (8–6, 1 abstention, July 23). The original nomination was withdrawn by the nominator, but FDA elected to proceed with the presentation of BPC-157 free base and BPC-157 acetate to the committee. The votes are advisory and not binding. FDA makes the final determination, and inclusion requires proposed and final rulemaking, with formal approval by the Secretary of Health and Human Services. None of the six is legal to compound on the strength of the vote alone; reporting at the time put the earliest realistic timeline at roughly twelve months.
FDA reviewers noted the absence of human injectable trial data. The available human pharmacokinetic evidence was limited to two studies of rectally administered BPC-157, in which plasma concentrations were largely undetectable. FDA career reviewers published briefing documents recommending against all seven substances, concluding that none met the agency's four-part evidentiary standard.
Category 2 is not a ban and not a scheduling action. It describes where a nominated substance sits in an unfinished evaluation process. An interim FDA designation for nominated bulk drug substances for which the agency identified potential significant safety risks. Substances in Category 2 sit outside FDA's Category 1 enforcement-discretion policy.
These are the specific, documented failure modes that lot-level third-party analysis addresses. A report reachable from the lot code printed on the vial — without asking the seller for it — is the only document that answers 'is this vial what the label says'. That is why every Vectra vial carries a QR code resolving to its own lot's published report.
Findings reported by commercial testing providers. Each names its source; none is registry- or peer-review-grade, so read them as a documented pattern rather than established prevalence.
Yes, and altered certificates have been reported in this market at material rates — see the testing findings above. Three properties make a report hard to fake:
Peptide identity data in the vendor market is often wrong in ways that are hard to see. Near-identical compounds get their CAS numbers, residue ranges, formulas and molecular weights swapped. A certificate can be internally consistent and still describe a different molecule than the label names. Most commercial peptide material ships as an acetate salt, not free base. The two forms have different measured masses, so a figure quoted against the wrong one will not reconcile. A report that does not state which form it assayed cannot be checked at all.
The standard our own reports are built to meet:
FDA has acted in this market between 2024 and 2026. Actions include a civil forfeiture over $1.7 million against a compounding operation, several rounds of warning letters to peptide vendors, and more than thirty letters in March 2026 concerning compounded GLP-1 products.
Buyers here increasingly compare document trail, not price.